Free
Critical Care Medicine  |   May 2010
Hydrocortisone Supplementation Enhances Hemodynamic Stability in Brain-dead Patients
Author Affiliations & Notes
  • Armelle Nicolas-Robin, M.D.
    *
  • Jérome D. Barouk, M.D.
    *
  • Julien Amour, M.D., Ph.D.
  • Pierre Coriat, M.D.
  • Bruno Riou, M.D., Ph.D.
    §
  • Olivier Langeron, M.D., Ph.D.
  • * Staff Anesthesiologist, Department of Anesthesiology and Critical Care, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. † Assistant Professor of Anesthesiology, ‡ Professor of Anesthesiology and Critical Care, Chairman, ∥ Professor of Anesthesiology and Critical Care, Department of Anesthesiology and Critical Care, § Professor of Anesthesiology and Critical Care, Chairman, Department of Emergency Medicine and Surgery, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie—Paris 6, Paris, France.
Article Information
Critical Care Medicine / Cardiovascular Anesthesia / Central and Peripheral Nervous Systems / Critical Care / Endocrine and Metabolic Systems
Critical Care Medicine   |   May 2010
Hydrocortisone Supplementation Enhances Hemodynamic Stability in Brain-dead Patients
Anesthesiology 5 2010, Vol.112, 1204-1210. doi:10.1097/ALN.0b013e3181d4f34d
Anesthesiology 5 2010, Vol.112, 1204-1210. doi:10.1097/ALN.0b013e3181d4f34d
What We Already Know about This Topic
  • ❖ Hemodynamic instability is common in brain-dead patients
  • ❖ Although hydrocortisone infusion is recommended in this setting, its efficacy has not been examined
What This Article Tells Us That Is New
  • ❖ In 31 brain-dead patients, adrenal insufficiency was present in 87%
  • ❖ Hydrocortisone infusion significantly reduced the dose of norepinephrine required for hemodynamic stability
DESPITE improved management and stabilization of patients on the transplant waiting list, the mortality during this period in the United States, as in other countries, has remained as high as 15% in 2005, with 42% of patients waiting for more than 2 yr.1 Thus, increasing the number of potential donors is a real challenge. Hemodynamic instability occurs in 80% of the potential donors, and it is at the origin of 10% of lost potential donors because of refractory hypotension despite adapted fluid infusion and norepinephrine administration.2 Although 60% of hemodynamic instabilities are corrected with fluids and norepinephrine infusion, vasopressors are known to be an independent risk factor of cardiac dysfunction in brain-dead patients and to delay renal graft function.3,4 
Adrenal insufficiency may be primary due to impairment of adrenal glands dysfunction or secondary due to impairment of pituitary gland and/or hypothalamus, or both (hypothalamic-pituitary-adrenal insufficiency). Disruption of the hypothalamic-pituitary-adrenal axis could contribute to hemodynamic instability in brain-dead patients because of the decrease in circulating levels of cortisol-adrenocorticotropic hormone (ACTH) and arginine-vasopressin. Critical illness-related adrenal insufficiency is now well described, and the benefit of hydrocortisone supplementation has been suggested in patients with vasopressor-dependent septic shock and in patients with early severe acute respiratory distress syndrome.5 Despite the fact that supplementation with intravenous hydrocortisone infusion is already recommended in brain-dead patients with hemodynamic instability,6 the effectiveness of this treatment has never been evaluated. The aim of this study was to investigate the benefit of supplementary-dose hydrocortisone in brain-dead patients in decreasing hemodynamic instability and norepinephrine requirements.
Materials and Methods
Patient Selection
All brain-dead patients 18 yr or older admitted to our intensive care unit during a 7-month period and who required norepinephrine were included prospectively. Before inclusion, brain death was diagnosed clinically with usual criteria (unresponsiveness to noxious pain stimuli, abolition of brainstem reflexes and apnea in the absence of hypothermia, metabolic or electrolyte disturbances, and depressant drugs) and then was confirmed with cerebral angiography or electroencephalography. The inclusion of the patients in the study was performed before any discussion with families about potential organ donation. Patients were excluded in case of severe cardiac failure defined by echocardiographic left ventricular ejection fraction less than 50%, sepsis, or if they had received corticosteroids during the previous 7 days or etomidate during the previous 3 days.7 
The study was approved by our ethics committee (Comité de Protection des Personnes se prêtant à la Recherche Biomédicale de l'Hôpital Pitié-Salpêtrière, Paris, France) and was performed in accordance with the Declaration of Helsinki. Waived informed consent was authorized because diagnosis of adrenal insufficiency and hormone resuscitation are routinely performed in our unit for the assessment of brain-dead patients and because interventional procedures to evaluate the potential organ donor are authorized before the presumed consent could be verified. This study was also conducted in accordance with French laws concerning multiple organ procurement.
Study Protocol
Hemodynamic Evaluation.
All patients were fully equipped with continuous heart rate monitoring and an indwelling radial artery catheter for continuous arterial blood pressure assessment. All patients were tracheally intubated and ventilated in a pressure-controlled mode with peak airway pressures adjusted to deliver a constant tidal volume of 8–10 ml/kg body weight and was maintained at less than 25 cm H2O. If necessary, respiratory rate was increased to obtain normocapnia.8 The inspiratory-to-expiratory time ratio was set to 1:2, and positive end-expiratory pressure was set at 5 cm H2O. Left ventricular systolic function assessment was performed with transesophageal echocardiography. Preload assessment was performed with respiratory variation of arterial pulse pressure measurement (ΔPP). If ΔPP was superior or equal to 13%, fluid loading was performed with 500 ml of a colloidal solution (Gelofusine®; B.Braun Medical, Boulogne-Billancourt, France) infused over 30 min and adjusted to obtain ΔPP less than 13%, suggesting that no significant hemodynamic improvement would be expected with further fluid challenge.9,10 After optimization of fluid loading, and only if required, the dose of norepinephrine was adjusted to obtain a mean arterial pressure between 65 and 90 mmHg.11 Apart from norepinephrine, no inotropic agent was used in these patients without major decrease in left ventricular ejection fraction. Diabetes insipidus (defined as a diuresis >4 ml · kg−1· h−1and urine density less than 1.003 g/cm3in the absence of urinary glucose or less than 1.005 g/cm3in the presence of urinary glucose) was treated with a single intravenous 1 μg desmopressin bolus.12 
ACTH Stimulation Testing.
After hemodynamic stabilization had been obtained for at least 60 min (i.e.  , mean arterial pressure maintained between 65 and 90 mmHg after correction of hypovolemia and stable concentration of norepinephrine infused continuously), the capacity of adrenal gland to respond to tetracosactrin was tested with the use of the standard short tetracosactrin test, which measured the total plasma cortisol concentration before (T0, baseline cortisol concentration), 30 min (T30stimulated cortisol concentration), and 60 min (T60stimulated cortisol concentration) after an intravenous injection of 250 μg of tetracosactrin (Synacthène®; Novartis Pharma SAS, Rueil Malmaison, France). Delta percentage of baseline plasma cortisol was calculated at T60as 100 × (plasma cortisol concentration T60− cortisol plasma concentration T0)/plasma cortisol concentration T0. Adrenal insufficiency was defined as baseline plasma cortisol concentration less than 15 μg/dl and/or delta plasma cortisol concentration less than 9 μg/dl in response to 250 μg tetracosactrin, measured at T30or T60.13 Delta plasma cortisol concentration more than 9 μg/dl defined “ACTH responder” patients, whereas delta plasma cortisol concentration less than 9 μg/dl defined “ACTH nonresponder” patients.5 
Norepinephrine Dose Adjustment.
After ACTH stimulation testing, patients were treated with a single intravenous injection of hydrocortisone (50 mg; Roussel-Uclaf, Romainville, France). Every 15 min for 180 min, the norepinephrine dose was adjusted to maintain mean arterial pressure between 65 and 90 mmHg. After 180 min, delta percentage of baseline norepinephrine dose more than or equal to 30% defined “hemodynamic responders,” and delta percentage of baseline norepinephrine dose less than 30% defined “hemodynamic nonresponders.”
Endpoints
The primary endpoint was hemodynamic stability assessed by the norepinephrine dose required after hydrocortisone infusion. The secondary endpoint was to assess the incidence of adrenal insufficiency incidence in brain-dead patients.
Statistical Analysis
A sample size of 28 patients was needed to achieve a statistical power of 90% and an α-risk of 5% to detect a decrease by 30% the norepinephrine dose when the initial mean norepinephrine dose was 0.4 μg · kg−1· min−1before treatment in our population of brain-dead patients (preliminary data not shown).
Data are expressed as mean ± SD for parametric variables or median (25–75 interquartiles) for nonparametric variables, or number (percentage and its 95% CI). Comparison of means was performed using the Student t  test for parametric variables or the Mann–Whitney U test for nonparametric variables. All P  values were two tailed, and a P  value <0.05 was considered significant. Statistical analysis was performed using NCSS 2007 software (Statistical Solutions Ltd., Cork, Ireland).
Results
Forty-two consecutive brain-dead patients were screened in this prospective study. Six patients were treated with corticosteroids during the previous 7 days, one patient did not require norepinephrine infusion, and five patients had echocardiographic left ventricular ejection fraction less than 50%. Therefore, 31 patients were included in the study, and their baseline characteristics are presented in table 1.
Table 1.  Baseline Characteristics of Patients
Image Not Available
Table 1.  Baseline Characteristics of Patients
×
Adrenal Insufficiency and Response to ACTH Stimulation
The incidence of adrenal insufficiency was 87% [95% CI, 70–96%]. In 85% [95% CI, 66–96%] of the cases, the adrenal insufficiency was total (hypothalamic-pituitary-adrenal insufficiency) or secondary (fig. 1). Twenty-four patients were ACTH responders (77% [95%CI, 55–87]), whereas seven were ACTH nonresponders (23% [95%CI, 10–41]) (fig. 1). Time between cerebral injury and brain death diagnosis was longer in ACTH responders than in ACTH nonresponders (6 ± 6 vs.  1 ± 0 days, respectively, P  < 0.05) (fig. 2).
Fig. 1. Distribution of patients according to baseline plasma cortisol concentration and response to cortisol-adrenocorticotropic hormone (ACTH) stimulation. Δ cortisol = delta plasma cortisol concentration 30 or 60 min after 250 μg of tetracosactrin infusion; HPAI = hypothalamic-pituitary–adrenal insufficiency; AI = adrenal insufficiency (see definition in Study Protocol—ACTH Stimulation Testing section); HR = hemodynamic responders (see definition in Study Protocol—Norepinephrine Dose Adjustment section).
Image Not Available
Fig. 1. Distribution of patients according to baseline plasma cortisol concentration and response to cortisol-adrenocorticotropic hormone (ACTH) stimulation. Δ cortisol = delta plasma cortisol concentration 30 or 60 min after 250 μg of tetracosactrin infusion; HPAI = hypothalamic-pituitary–adrenal insufficiency; AI = adrenal insufficiency (see definition in Study Protocol—ACTH Stimulation Testing section); HR = hemodynamic responders (see definition in Study Protocol—Norepinephrine Dose Adjustment section).
×
Fig. 2. Comparison of time between brain injury and brain death between cortisol-adrenocorticotropic hormone (ACTH) responders and ACTH nonresponders (see definition of ACTH in Study Protocol—ACTH Stimulation Testing section). Data are box plot  (median, 25th and 75th percentiles, and whiskers  ).
Image Not Available
Fig. 2. Comparison of time between brain injury and brain death between cortisol-adrenocorticotropic hormone (ACTH) responders and ACTH nonresponders (see definition of ACTH in Study Protocol—ACTH Stimulation Testing section). Data are box plot  (median, 25th and 75th percentiles, and whiskers  ).
×
Initial Glasgow Coma Score, systemic hemodynamics, total fluid infusion, and norepinephrine dose were not significantly different between patients with or without adrenal insufficiency (table 2). At T0, baseline plasma cortisol was significantly lower in ACTH responders than in ACTH nonresponders (5.5 [3.0–9.2]μg/dl vs.  14.5[9.9–33.5]μg/dl, respectively, P  < 0.01). In patients with adrenal insufficiency, baseline plasma cortisol was significantly lower than in patients without adrenal insufficiency (fig. 3A). In contrast, there was no significant difference between the concentration of baseline plasma cortisol in hemodynamic responders and hemodynamic nonresponders (fig. 3B). After ACTH stimulation testing, delta percentage of baseline plasma cortisol concentration at T60was not significantly different between patients with or without adrenal insufficiency (fig. 3C) and between hemodynamic responders and hemodynamic nonresponders (fig. 3D).
Table 2.  Characteristics of Patients with Adrenal Insufficiency and No Adrenal Insufficiency
Image Not Available
Table 2.  Characteristics of Patients with Adrenal Insufficiency and No Adrenal Insufficiency
×
Fig. 3. Comparison of baseline plasma cortisol concentration and delta percentage of baseline plasma cortisol concentration at T60between patients with (AI+) and without (AI−) adrenal insufficiency (see definition in Study Protocol–ACTH Stimulation Testing section) (A  , C  ) and between hemodynamic responders (HR+) and hemodynamic nonresponders (HR−) (see definition in Study Protocol—Norepinephrine Dose Adjustment section) (B  , D  ). Data are box plot  (medians, 25th and 75th percentiles, and whiskers  ). NS = nonsignificant.
Image Not Available
Fig. 3. Comparison of baseline plasma cortisol concentration and delta percentage of baseline plasma cortisol concentration at T60between patients with (AI+) and without (AI−) adrenal insufficiency (see definition in Study Protocol–ACTH Stimulation Testing section) (A  , C  ) and between hemodynamic responders (HR+) and hemodynamic nonresponders (HR−) (see definition in Study Protocol—Norepinephrine Dose Adjustment section) (B  , D  ). Data are box plot  (medians, 25th and 75th percentiles, and whiskers  ). NS = nonsignificant.
×
Total Norepinephrine Dose
In all patients, total norepinephrine dose significantly decreased at 180 min after ACTH stimulation testing and hydrocortisone infusion, from 0.31 [0.16–0.44]μg · kg−1· min−1to 0.18 [0.10–0.24]μg · kg−1· min−1(P  < 0.01), without significant decrease in mean arterial blood pressure (from 81 ± 12 mmHg to 83 ± 9 mmHg, nonsignificant). The initial norepinephrine dose was similar in patients with or without adrenal insufficiency (0.31 [0.18–0.48]μg · kg−1· min−1and 0.31 [0.16–0.49]μg · kg−1· min−1, respectively, nonsignificant). The delta percentage of baseline norepinephrine dose, reflecting the hemodynamic response intensity, was similar in patients with or without adrenal insufficiency (−47% vs.  −15%, respectively, nonsignificant) and was similar in ACTH responders and nonresponders (−28% vs.  −50%, respectively, nonsignificant). A hemodynamic response was obtained in 18 patients (58% [95% CI, 39–75]). However, the incidence of hemodynamic response was higher in ACTH nonresponders than in ACTH responders: 86% versus  50%, respectively, P  < 0.05 (fig. 1). The hemodynamic response intensity was independent of the response to ACTH stimulation testing and independent of the presence or type of adrenal insufficiency.
Discussion
Hydrocortisone supplementation significantly enhanced systemic hemodynamics and decreased norepinephrine dose by more than 30% in 58% of brain-dead patients with hemodynamic instability. In our study, 87% of brain-dead patients had adrenal insufficiency, which resulted from a low plasma cortisol concentration in three quarters of cases (secondary adrenal insufficiency) and a lack of response to ACTH stimulation in one quarter of cases (primary adrenal insufficiency). A hemodynamic response occurred more frequently in patients with primary adrenal insufficiency.
In our study, the incidence of adrenal insufficiency is in agreement with previous studies in which adrenal insufficiency was defined by a stimulated plasma cortisol concentration less than 18 μg/dl.14 Previous studies investigating the adequacy of cortisol secretion in the setting of brain death have led to variable conclusions. On the basis of baseline plasma cortisol concentration, corticosteroid function in brain-dead patients was still a matter of debate,14–17 being found as normal,18 decreased,19 or increased.17 The prevalence of adrenal insufficiency varies widely, depending on the diagnostic criteria. There is no absolute plasma cortisol concentration, which distinguishes an adequate from an insufficient adrenal response. However, a baseline plasma cortisol concentration less than 15 μg/dl has been suggested to be inadequate in critical illness situations.13 
In our study, 24 of 31 patients (77%) were ACTH responders. In brain-dead patients, Dimopoulou et al.  14 found that only 4 of 17 patients (24%) were ACTH responders. However, they used a different definition: ACTH responders were defined by a delta plasma cortisol concentration more than 18 μg/dl. Moreover, they used a less specific ACTH stimulation testing (1 μg)18 compared with the recommended test used in our study (250 μg).5 
Among brain-dead patients, we can distinguish four pathophysiologic groups according to baseline and stimulated plasma cortisol concentration. (1) Approximately two thirds of patients have a low baseline plasma cortisol concentration and are ACTH responders, reflecting a hypothalamic-pituitary failure (secondary adrenal insufficiency).20 Intracranial hypertension may impair oxygenation of the hypothalamus and pituitary, being responsible for a low release of corticotropin-releasing hormone and ACTH. After tetracosactrin infusion, the intact adrenal glands produce cortisol. (2) Approximately 10% of patients have a normal baseline cortisol concentration and are ACTH nonresponders, suggesting a maximal stimulation of the hypothalamic-pituitary-adrenal axis and thus a relative primary adrenal insufficiency21 : adrenal glands cannot increase their production of cortisol, which is insufficient in regard to the stress-induced needs. (3) Approximately 10% of patients have a low baseline cortisol concentration and are ACTH nonresponders, reflecting a hypothalamic-pituitary-adrenal insufficiency. (4) Approximately 10% of patients have a normal baseline cortisol concentration and are ACTH responders, suggesting no hypothalamic-pituitary-adrenal axis dysfunction.
The value of supplementary dose of hydrocortisone infusion has been demonstrated variously in patients with septic shock.22,23 Annane et al.  21 demonstrated that 7-day shock reversal was achieved significantly more often in treated patients versus  in controlled patients, implying a decrease in mortality rate of 31%. The Corticosteroid Therapy of Septic Shock study did not confirm these results, maybe partly because of the lower severity of illness in enrolled patients.23 These results were independent of the responsiveness to a short corticotropin test.24 In our study, we demonstrated that supplementary dose of hydrocortisone infusion was more often efficient in enhancing hemodynamic stability in ACTH nonresponders (86%) than in ACTH responders (46%), suggesting that exogenous steroids have a higher likelihood of producing a hemodynamic response when there is no endogenous response to ACTH stimulation. Supplementary dose of hydrocortisone infusion was efficient in some patients without any adrenal insufficiency too (50%), suggesting a possible corticosteroid tissue resistance. In 22% of patients, the lack of response to ACTH stimulation testing suggests the absence of cortisol adrenal reserve. Moreover, as described in patients with septic shock,25 the time between brain injury and brain death seems to be playing an important role in response to ACTH stimulation testing and hemodynamic response intensity. These results could be explained by the fact that corticosteroid effects result from the restoration of α- and β-adrenoceptors pathway26,27 altered by down-regulation and later by desensitization28 in patients with shock treated with catecholamines. In brain injury, an explosive increase in intracranial pressure is also known to induce a systemic peak of catecholamines release followed by a drop 60 min after the brain death onset.29 After the initial stress at the origin of large cortisol release, the overstimulated hypothalamic-pituitary-adrenal axis adrenal gland induced by brain death may be unable to restore the stock of cortisol. In our study, the effectiveness of hydrocortisone infusion on norepinephrine dose decrease was observed in one quarter of patients with a baseline plasma concentration more than 15 μg/dl and no ACTH response. As established, septic shock, down-regulation of β-adrenergic receptors,28 and possibly α-adrenergic receptors30 may contribute to the vascular hyporesponsiveness to catecholamines. In addition, as recently shown in different myocardial pathology, overexpression of β3-adrenoceptor could be involved as well.30,31 Negative inotropic effect induced by β3-adrenoceptor in parallel to down-regulation of β1-adrenoceptor is known to decrease inotropic effect of β-adrenergic stimulation, whereas the increase of sympathic drive is an important mechanism for maintaining cardiac output. In this way, corticosteroids may reverse receptor desensitization26,27 and further allow reduced catecholamine dosage. Methylprednisolone may improve hemodynamics31 and restore the normal β1-adrenoceptor/β3-adrenoceptor ratio in patients with circulatory shock treated with catecholamines for more than or equal to 72 h, whereas earlier glucocorticoid infusion does not improve hemodynamics.
Beneficial effects of glucocorticoids in brain death could be also induced by their antiinflammatory effect. Because adrenal insufficiency results from multiple cytokine release such as tumor necrosis factor α, interleukin-1, interleukin-6, and overexpression of cell adhesion molecules such as intercellular adhesion molecule-1 and E-selectin,32,33 hydrocortisone treatment may decrease the proinflammatory response.34 
To summarize, baseline cortisol measurement and ACTH stimulation testing are useful to distinguish the type of adrenal insufficiency but cannot predict which brain-dead patients are hemodynamic responders, even if most of ACTH nonresponders are hemodynamic responders. Conversely, no adverse effect has been reported with ACTH stimulation testing or with low-dose glucocorticoid infusion. For this reason, and because no adverse effect has never been reported, we suggest to test the adrenal response to ACTH stimulation and infuse a supplementary dose of hydrocortisone in all brain-dead patients with hemodynamic instability requiring norepinephrine.
Several limitations of our study should be noted. First, because this study was not randomized, a causality link cannot be demonstrated concerning the administration of glucocorticoids and the changes observed in norepinephrine dose. Nevertheless, we assume that, because hemodynamic stability, and thus norepinephrine dose, was ensured during a 60-min period before glucocorticoid administration and because patients with severe cardiac dysfunction had been excluded, this causality link remains likely. Moreover, the comparison between subgroups remains valid. Second, we did not assess the consequences of glucocorticoid administration on the prognosis of organ transplantation. It should be pointed out that these consequences would be difficult to analyze because brain-dead patients receive high doses of glucocorticoids for immunogic purposes just before organ harvesting. Conversely, a recent study has demonstrated that high dose of vasoactive drugs in donor was a major determinant for primary graft failure in heart transplantation.35 Further evaluation would be useful to evaluate the benefit of the decrease of norepinephrine requirement in donors for cardiac and other transplants. Third, because measurement of the free cortisol concentration is currently not widely available, we measured total plasma cortisol concentration, rather than the protein-bound fraction, whereas the free cortisol is responsible for the physiologic function of the hormone. In critical illness, the concentrations of albumin and corticosteroid-binding globulin are commonly decreased. Therefore, measured total plasma cortisol concentration can be misleadingly lower than anticipated, resulting in the incorrect conclusion that adrenal function is impaired.36 However, these considerations do not change the hemodynamic response incidence and intensity, which was the aim of our study. In any event, further studies are necessary to establish the normal range of free cortisol in critically ill patient, and experts do not recommend the use of free cortisol measurements for the diagnosis of adrenal insufficiency at this time.5 
In conclusion, our findings suggest that the incidence of adrenal insufficiency is important in brain-dead patients (87%) and that ACTH stimulation followed 1 h later by a supplementary dose of hydrocortisone enhanced the systemic hemodynamic stability whatever their pathophysiologic corticosteroid status, with or without primary and/or secondary adrenal insufficiency.
The authors thank the nurse team and the hospital coordinating the organ procurement team (Joelle Florit, nurse; Viviane Justice, nurse; Véronique Kokoszka-Biscompte, nurse; and Isabelle Oilic, nurse; all from Coordination of Tissue and Organ Harvesting, Groupe Hospitalier Pitié-Salpêtrière, Paris, France) for their help with this study. They also thank David Baker, D.M., F.R.C.A. (Staff Anesthesiologist, Department of Anesthesiology, Centre Hospitalo-Universitaire Necker-Enfants Malades, Paris, France), for reviewing the manuscript.
References
Garrity ER, Moore J, Mulligan MS, Shearon TH, Zucker MJ, Murray S: Heart and lung transplantation in the United States, 1996–2005. Am J Transplant 2007; 7:1390–403Garrity, ER Moore, J Mulligan, MS Shearon, TH Zucker, MJ Murray, S
Salim A, Martin M, Brown C, Rhee P, Demetriades D, Belzberg H: The effect of a protocol of aggressive donor management: Implications for the national organ donor shortage. J Trauma 2006; 61:429–33Salim, A Martin, M Brown, C Rhee, P Demetriades, D Belzberg, H
Giral M, Bertola JP, Foucher Y, Villers D, Bironneau E, Blanloeil Y, Karam G, Daguin P, Lerat L, Soulillou JP: Effect of brain-dead donor resuscitation on delayed graft function: Results of a monocentric analysis. Transplantation 2007; 83:1174–81Giral, M Bertola, JP Foucher, Y Villers, D Bironneau, E Blanloeil, Y Karam, G Daguin, P Lerat, L Soulillou, JP
Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ: Donor employment of vasopressors and its impact on allograft survival after transplantation. Transplant Proc 2001; 33:1282–3Schnuelle, P Berger, S de Boer, J Persijn, G van der Woude, FJ
Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, Keh D, Briegel J, Beishuizen A, Dimopoulou I, Tsagarakis S, Singer M, Chrousos GP, Zaloga G, Bokhari F, Vogeser M: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36:1937–49Marik, PE Pastores, SM Annane, D Meduri, GU Sprung, CL Arlt, W Keh, D Briegel, J Beishuizen, A Dimopoulou, I Tsagarakis, S Singer, M Chrousos, GP Zaloga, G Bokhari, F Vogeser, M
Zaroff JG, Rosengard BR, Armstrong WF, Babcock WD, D'Alessandro A, Dec GW, Edwards NM, Higgins RS, Jeevanandum V, Kauffman M, Kirklin JK, Large SR, Marelli D, Peterson TS, Ring WS, Robbins RC, Russell SD, Taylor DO, Van Bakel A, Wallwork J, Young JB: Consensus conference report: Maximizing use of organs recovered from the cadaver donor: Cardiac recommendations, March 28–29, 2001, Crystal City, VA. Circulation 2002; 106:836–41Zaroff, JG Rosengard, BR Armstrong, WF Babcock, WD D'Alessandro, A Dec, GW Edwards, NM Higgins, RS Jeevanandum, V Kauffman, M Kirklin, JK Large, SR Marelli, D Peterson, TS Ring, WS Robbins, RC Russell, SD Taylor, DO Van Bakel, A Wallwork, J Young, JB
Vinclair M, Broux C, Faure P, Brun J, Genty C, Jacquot C, Chabre O, Payen JF: Duration of adrenal inhibition following a single dose of etomidate in critically ill patients. Intensive Care Med 2008; 34:714–9Vinclair, M Broux, C Faure, P Brun, J Genty, C Jacquot, C Chabre, O Payen, JF
De Backer D, Taccone FS, Holsten R, Ibrahimi F, Vincent JL: Influence of respiratory rate on stroke volume variation in mechanically ventilated patients. Anesthesiology 2009; 110:1092–7De Backer, D Taccone, FS Holsten, R Ibrahimi, F Vincent, JL
Magder S: Clinical usefulness of respiratory variations in arterial pressure. Am J Respir Crit Care Med 2004; 169:151–5Magder, S
Preisman S, Kogan S, Berkenstadt H, Perel A: Predicting fluid responsiveness in patients undergoing cardiac surgery: Functional haemodynamic parameters including the Respiratory Systolic Variation Test and static preload indicators. Br J Anaesth 2005; 95:746–55Preisman, S Kogan, S Berkenstadt, H Perel, A
Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB: Care of the potential organ donor. N Engl J Med 2004; 351:2730–9Wood, KE Becker, BN McCartney, JG D'Alessandro, AM Coursin, DB
Guesde R, Barrou B, Leblanc I, Ourahma S, Goarin J-P, Coriat P, Riou B: Administration of desmopressin in brain-dead donors and renal function in kidney recipients. Lancet 1998; 352:1178–81Guesde, R Barrou, B Leblanc, I Ourahma, S Goarin, JP Coriat, P Riou, B
Cooper MS, Stewart PM: Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727–34Cooper, MS Stewart, PM
Dimopoulou I, Tsagarakis S, Anthi A, Milou E, Ilias I, Stavrakaki K, Charalambidis C, Tzanela M, Orfanos S, Mandragos K, Thalassinos N, Roussos C: High prevalence of decreased cortisol reserve in brain-dead potential organ donors. Crit Care Med 2003; 31:1113–7Dimopoulou, I Tsagarakis, S Anthi, A Milou, E Ilias, I Stavrakaki, K Charalambidis, C Tzanela, M Orfanos, S Mandragos, K Thalassinos, N Roussos, C
Novitzky D, Cooper DK, Reichart B: Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 1987; 43:852–4Novitzky, D Cooper, DK Reichart, B
Gramm HJ, Meinhold H, Bickel U, Zimmermann J, von Hammerstein B, Keller F, Dennhardt R, Voigt K: Acute endocrine failure after brain death? Transplantation 1992; 54:851–7Gramm, HJ Meinhold, H Bickel, U Zimmermann, J von Hammerstein, B Keller, F Dennhardt, R Voigt, K
Powner DJ, Hendrich A, Lagler RG, Ng RH, Madden RL: Hormonal changes in brain dead patients. Crit Care Med 1990; 18:702–8Powner, DJ Hendrich, A Lagler, RG Ng, RH Madden, RL
Lopau K, Mark J, Schramm L, Heidbreder E, Wanner C: Hormonal changes in brain death and immune activation in the donor. Transpl Int 2000; 13(suppl 1):S282–5Lopau, K Mark, J Schramm, L Heidbreder, E Wanner, C
Howlett TA, Keogh AM, Perry L, Touzel R, Rees LH: Anterior and posterior pituitary function in brain-stem-dead donors. A possible role for hormonal replacement therapy. Transplantation 1989; 47:828–34Howlett, TA Keogh, AM Perry, L Touzel, R Rees, LH
Novitzky D, Cooper DK, Muchmore JS, Zuhdi N: Pituitary function in brain-dead patients. Transplantation 1989; 48:1078–9Novitzky, D Cooper, DK Muchmore, JS Zuhdi, N
Annane D, Sebille V, Troche G, Raphael J-C, Gajdos P, Bellissant E: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038–45Annane, D Sebille, V Troche, G Raphael, JC Gajdos, P Bellissant, E
Annane D, Sebille V, Charpentier C, Bollaert P-E, Francois B, Korach J-M, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862–71Annane, D Sebille, V Charpentier, C Bollaert, PE Francois, B Korach, JM Capellier, G Cohen, Y Azoulay, E Troche, G Chaumet-Riffaut, P Bellissant, E
Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre P-F, Reinhart K, Cuthbertson BH, Payen D, Briegel J; CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111–24Sprung, CL Annane, D Keh, D Moreno, R Singer, M Freivogel, K Weiss, YG Benbenishty, J Kalenka, A Forst, H Laterre, PF Reinhart, K Cuthbertson, BH Payen, D Briegel, J CORTICUS Study Group,
Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645–50Bollaert, PE Charpentier, C Levy, B Debouverie, M Audibert, G Larcan, A
de Jong M, Beishuizen A, Spijkstra J-J, Girbes A, Strack van Schijndel R, Twisk J, Groeneveld ABJ: Predicting a low cortisol response to adrenocorticotrophic hormone in the critically ill: A retrospective cohort study. Crit Care 2007; 11:R61de Jong, M Beishuizen, A Spijkstra, JJ Girbes, A Strack van Schijndel, R Twisk, J Groeneveld, ABJ
Barnes PJ: Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995; 152:838–60Barnes, PJ
Walker BR, Williams BC: Corticosteroids and vascular tone: Mapping the messenger maze. Clin Sci (Lond) 1992; 82:597–605Walker, BR Williams, BC
Silverman HJ, Penaranda R, Orens JB, Lee NH: Impaired beta-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: Association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 1993; 21:31–9Silverman, HJ Penaranda, R Orens, JB Lee, NH
Shivalkar B, Van Loon J, Wieland W, Tjandra-Maga TB, Borgers M, Plets C, Flameng W: Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 1993; 87:230–9Shivalkar, B Van Loon, J Wieland, W Tjandra-Maga, TB Borgers, M Plets, C Flameng, W
McMillan M, Chernow B, Roth BL: Hepatic alpha 1-adrenergic receptor alteration in a rat model of chronic sepsis. Circ Shock 1986; 19:185–93McMillan, M Chernow, B Roth, BL
Saito T, Fuse A, Gallagher ET, Cutler S, Takanashi M, Yamada K, Carlsson C, Carney E, Abou-Sayf FK, Ogawa R: The effect of methylprednisolone on myocardial beta-adrenergic receptors and cardiovascular function in shock patients. Shock 1996; 5:241–6Saito, T Fuse, A Gallagher, ET Cutler, S Takanashi, M Yamada, K Carlsson, C Carney, E Abou-Sayf, FK Ogawa, R
Amado JA, Lopez-Espadas F, Vazquez-Barquero A, Salas E, Riancho JA, Lopez-Cordovilla JJ, Garcia-Unzueta MT: Blood levels of cytokines in brain-dead patients: Relationship with circulating hormones and acute-phase reactants. Metabolism 1995; 44:812–6Amado, JA Lopez-Espadas, F Vazquez-Barquero, A Salas, E Riancho, JA Lopez-Cordovilla, JJ Garcia-Unzueta, MT
Birks EJ, Burton PBJ, Owen V, Mullen AJ, Hunt D, Banner NR, Barton PJR, Yacoub MH: Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 2000; 102:III352–8Birks, EJ Burton, PBJ Owen, V Mullen, AJ Hunt, D Banner, NR Barton, PJR Yacoub, MH
McLean KM, Duffy JY, Pandalai PK, Lyons JM, Bulcao CF, Wagner CJ, Akhter SA, Pearl JM: Glucocorticoids alter the balance between pro- and anti-inflammatory mediators in the myocardium in a porcine model of brain death. J Heart Lung Transplant 2007; 26:78–84McLean, KM Duffy, JY Pandalai, PK Lyons, JM Bulcao, CF Wagner, CJ Akhter, SA Pearl, JM
Santise G, D'Ancona G, Falletta C, Pirone F, Sciacca S, Turrisi M, Biondo D, Pilato M: Donor pharmacological hemodynamic support is associated with primary graft failure in human heart transplantation. Interact Cardiovasc Thorac Surg 2009; 9:476–9Santise, G D'Ancona, G Falletta, C Pirone, F Sciacca, S Turrisi, M Biondo, D Pilato, M
Hamrahian AH, Oseni TS, Arafah BM: Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629–38Hamrahian, AH Oseni, TS Arafah, BM
Fig. 1. Distribution of patients according to baseline plasma cortisol concentration and response to cortisol-adrenocorticotropic hormone (ACTH) stimulation. Δ cortisol = delta plasma cortisol concentration 30 or 60 min after 250 μg of tetracosactrin infusion; HPAI = hypothalamic-pituitary–adrenal insufficiency; AI = adrenal insufficiency (see definition in Study Protocol—ACTH Stimulation Testing section); HR = hemodynamic responders (see definition in Study Protocol—Norepinephrine Dose Adjustment section).
Image Not Available
Fig. 1. Distribution of patients according to baseline plasma cortisol concentration and response to cortisol-adrenocorticotropic hormone (ACTH) stimulation. Δ cortisol = delta plasma cortisol concentration 30 or 60 min after 250 μg of tetracosactrin infusion; HPAI = hypothalamic-pituitary–adrenal insufficiency; AI = adrenal insufficiency (see definition in Study Protocol—ACTH Stimulation Testing section); HR = hemodynamic responders (see definition in Study Protocol—Norepinephrine Dose Adjustment section).
×
Fig. 2. Comparison of time between brain injury and brain death between cortisol-adrenocorticotropic hormone (ACTH) responders and ACTH nonresponders (see definition of ACTH in Study Protocol—ACTH Stimulation Testing section). Data are box plot  (median, 25th and 75th percentiles, and whiskers  ).
Image Not Available
Fig. 2. Comparison of time between brain injury and brain death between cortisol-adrenocorticotropic hormone (ACTH) responders and ACTH nonresponders (see definition of ACTH in Study Protocol—ACTH Stimulation Testing section). Data are box plot  (median, 25th and 75th percentiles, and whiskers  ).
×
Fig. 3. Comparison of baseline plasma cortisol concentration and delta percentage of baseline plasma cortisol concentration at T60between patients with (AI+) and without (AI−) adrenal insufficiency (see definition in Study Protocol–ACTH Stimulation Testing section) (A  , C  ) and between hemodynamic responders (HR+) and hemodynamic nonresponders (HR−) (see definition in Study Protocol—Norepinephrine Dose Adjustment section) (B  , D  ). Data are box plot  (medians, 25th and 75th percentiles, and whiskers  ). NS = nonsignificant.
Image Not Available
Fig. 3. Comparison of baseline plasma cortisol concentration and delta percentage of baseline plasma cortisol concentration at T60between patients with (AI+) and without (AI−) adrenal insufficiency (see definition in Study Protocol–ACTH Stimulation Testing section) (A  , C  ) and between hemodynamic responders (HR+) and hemodynamic nonresponders (HR−) (see definition in Study Protocol—Norepinephrine Dose Adjustment section) (B  , D  ). Data are box plot  (medians, 25th and 75th percentiles, and whiskers  ). NS = nonsignificant.
×
Table 1.  Baseline Characteristics of Patients
Image Not Available
Table 1.  Baseline Characteristics of Patients
×
Table 2.  Characteristics of Patients with Adrenal Insufficiency and No Adrenal Insufficiency
Image Not Available
Table 2.  Characteristics of Patients with Adrenal Insufficiency and No Adrenal Insufficiency
×